$MCRB
Seres Therapeutics, Inc.

2021 Q2 Form 10-Q Financial Statement

#000095017021000674 Filed on August 03, 2021

View on sec.gov

Income Statement

Concept 2021 Q2 2020 Q2
Revenue $5.263M $6.045M
YoY Change -12.94% -51.76%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $17.45M $6.490M
YoY Change 168.89% 16.52%
% of Gross Profit
Research & Development $35.95M $20.10M
YoY Change 78.88% 12.25%
% of Gross Profit
Depreciation & Amortization $1.426M $1.691M
YoY Change -15.67% -11.97%
% of Gross Profit
Operating Expenses $53.41M $26.59M
YoY Change 100.85% 13.25%
Operating Profit -$48.14M -$20.55M
YoY Change 134.32% 87.66%
Interest Expense $97.00K -$650.0K
YoY Change -114.92% -443.92%
% of Operating Profit
Other Income/Expense, Net -$188.0K -$169.0K
YoY Change 11.24% -189.42%
Pretax Income -$48.33M -$20.71M
YoY Change 133.37% 92.47%
Income Tax $0.00 $0.00
% Of Pretax Income
Net Earnings -$48.33M -$20.71M
YoY Change 133.32% 92.53%
Net Earnings / Revenue -918.3% -342.66%
Basic Earnings Per Share -$0.53
Diluted Earnings Per Share -$0.53 -$282.5K
COMMON SHARES
Basic Shares Outstanding 91.66M
Diluted Shares Outstanding 91.66M

Balance Sheet

Concept 2021 Q2 2020 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $214.6M $63.90M
YoY Change 235.76% -37.48%
Cash & Equivalents $74.00M $61.54M
Short-Term Investments $140.6M $2.400M
Other Short-Term Assets $8.751M $5.800M
YoY Change 50.88% 11.54%
Inventory
Prepaid Expenses
Receivables $1.251M $2.929M
Other Receivables $0.00 $0.00
Total Short-Term Assets $224.6M $72.72M
YoY Change 208.81% -33.28%
LONG-TERM ASSETS
Property, Plant & Equipment $15.05M $16.31M
YoY Change -7.72% -28.94%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $14.88M
YoY Change
Other Assets $602.0K $1.400M
YoY Change -57.0% -6.67%
Total Long-Term Assets $45.09M $27.98M
YoY Change 61.14% -24.57%
TOTAL ASSETS
Total Short-Term Assets $224.6M $72.72M
Total Long-Term Assets $45.09M $27.98M
Total Assets $269.6M $100.7M
YoY Change 167.77% -31.07%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $5.450M $4.200M
YoY Change 29.76% -11.84%
Accrued Expenses $10.88M $8.200M
YoY Change 32.66% 2.5%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due $6.298M
YoY Change
Total Short-Term Liabilities $56.17M $44.20M
YoY Change 27.07% 2.62%
LONG-TERM LIABILITIES
Long-Term Debt $19.04M $24.90M
YoY Change -23.55%
Other Long-Term Liabilities $1.119M $752.0K
YoY Change 48.8% 14.11%
Total Long-Term Liabilities $1.119M $752.0K
YoY Change 48.8% 14.11%
TOTAL LIABILITIES
Total Short-Term Liabilities $56.17M $44.20M
Total Long-Term Liabilities $1.119M $752.0K
Total Liabilities $168.6M $166.3M
YoY Change 1.4% 1.34%
SHAREHOLDERS EQUITY
Retained Earnings -$632.6M -$500.2M
YoY Change 26.45% 17.85%
Common Stock $733.6M $434.7M
YoY Change 68.78% 6.93%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $101.1M -$65.58M
YoY Change
Total Liabilities & Shareholders Equity $269.6M $100.7M
YoY Change 167.83% -31.09%

Cashflow Statement

Concept 2021 Q2 2020 Q2
OPERATING ACTIVITIES
Net Income -$48.33M -$20.71M
YoY Change 133.32% 92.53%
Depreciation, Depletion And Amortization $1.426M $1.691M
YoY Change -15.67% -11.97%
Cash From Operating Activities -$39.69M -$25.50M
YoY Change 55.65% 116.1%
INVESTING ACTIVITIES
Capital Expenditures -$2.596M -$200.0K
YoY Change 1198.0% -33.33%
Acquisitions
YoY Change
Other Investing Activities $49.09M $17.90M
YoY Change 174.22%
Cash From Investing Activities $46.49M $17.70M
YoY Change 162.66% -6000.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 549.0K 14.60M
YoY Change -96.24% -75.95%
NET CHANGE
Cash From Operating Activities -39.69M -25.50M
Cash From Investing Activities 46.49M 17.70M
Cash From Financing Activities 549.0K 14.60M
Net Change In Cash 7.348M 6.800M
YoY Change 8.06% -86.01%
FREE CASH FLOW
Cash From Operating Activities -$39.69M -$25.50M
Capital Expenditures -$2.596M -$200.0K
Free Cash Flow -$37.10M -$25.30M
YoY Change 46.62% 120.0%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
us-gaap Type Of Revenue Extensible List
TypeOfRevenueExtensibleList
us-gaap:LicenseAndServiceMember
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
CY2021Q2 us-gaap Type Of Revenue Extensible List
TypeOfRevenueExtensibleList
us-gaap:LicenseAndServiceMember
dei Entity Central Index Key
EntityCentralIndexKey
0001609809
dei Amendment Flag
AmendmentFlag
false
CY2021Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2020Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2021Q2 us-gaap Preferred Stock Value
PreferredStockValue
CY2020Q2 us-gaap Type Of Revenue Extensible List
TypeOfRevenueExtensibleList
us-gaap:LicenseAndServiceMember
us-gaap Type Of Revenue Extensible List
TypeOfRevenueExtensibleList
us-gaap:LicenseAndServiceMember
CY2020Q4 us-gaap Preferred Stock Value
PreferredStockValue
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2021-06-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2021
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-37465
mcrb Revenue From Grant
RevenueFromGrant
1570000
dei Entity Registrant Name
EntityRegistrantName
Seres Therapeutics, Inc.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Trading Symbol
TradingSymbol
MCRB
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Local Phone Number
LocalPhoneNumber
945-9626
dei Security12b Title
Security12bTitle
Common Stock, par value $0.001
CY2020Q4 us-gaap Assets
Assets
342940000
CY2021Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
5450000
CY2020Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
4018000
CY2021Q2 mcrb Accrued Liabilities And Other Liabilities Current
AccruedLiabilitiesAndOtherLiabilitiesCurrent
18913000
CY2020Q4 mcrb Accrued Liabilities And Other Liabilities Current
AccruedLiabilitiesAndOtherLiabilitiesCurrent
14226000
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
27-4326290
dei Entity Address Address Line1
EntityAddressAddressLine1
200 Sidney Street - 4th Floor
dei Entity Address City Or Town
EntityAddressCityOrTown
Cambridge
dei Entity Address State Or Province
EntityAddressStateOrProvince
MA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
02139
dei City Area Code
CityAreaCode
617
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2021Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
91718571
CY2021Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
73997000
CY2020Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
116049000
CY2021Q2 us-gaap Short Term Investments
ShortTermInvestments
140556000
CY2020Q4 us-gaap Short Term Investments
ShortTermInvestments
137567000
CY2021Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
8751000
CY2020Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
5774000
CY2021Q2 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
1251000
CY2020Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
9387000
CY2021Q2 us-gaap Assets Current
AssetsCurrent
224555000
CY2020Q4 us-gaap Assets Current
AssetsCurrent
268777000
CY2021Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
15047000
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
13897000
CY2021Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
12415000
CY2020Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
9041000
CY2021Q2 us-gaap Restricted Investments Noncurrent
RestrictedInvestmentsNoncurrent
2150000
CY2020Q4 us-gaap Restricted Investments Noncurrent
RestrictedInvestmentsNoncurrent
1400000
CY2021Q2 us-gaap Long Term Investments
LongTermInvestments
14879000
CY2020Q4 us-gaap Long Term Investments
LongTermInvestments
49825000
CY2021Q2 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
602000
CY2021Q2 us-gaap Assets
Assets
269648000
CY2021Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
5675000
CY2020Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
5115000
CY2021Q2 us-gaap Notes Payable Current
NotesPayableCurrent
6298000
CY2020Q4 us-gaap Notes Payable Current
NotesPayableCurrent
454000
CY2021Q2 mcrb Contract With Customer Liability Current Related Party
ContractWithCustomerLiabilityCurrentRelatedParty
19829000
CY2020Q4 mcrb Contract With Customer Liability Current Related Party
ContractWithCustomerLiabilityCurrentRelatedParty
22602000
CY2021Q2 us-gaap Liabilities Current
LiabilitiesCurrent
56165000
CY2020Q4 us-gaap Liabilities Current
LiabilitiesCurrent
46415000
CY2021Q2 us-gaap Long Term Notes Payable
LongTermNotesPayable
19036000
CY2020Q4 us-gaap Long Term Notes Payable
LongTermNotesPayable
24639000
CY2021Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
13828000
CY2020Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
10561000
CY2021Q2 mcrb Contract With Customer Liability Noncurrent Related Party
ContractWithCustomerLiabilityNoncurrentRelatedParty
78434000
CY2020Q4 mcrb Contract With Customer Liability Noncurrent Related Party
ContractWithCustomerLiabilityNoncurrentRelatedParty
85572000
CY2021Q2 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
1119000
CY2020Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
1003000
CY2021Q2 us-gaap Liabilities
Liabilities
168582000
CY2020Q4 us-gaap Liabilities
Liabilities
168190000
CY2021Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2020Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2021Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2020Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2021Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2021Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2020Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2020Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2021Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2020Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2021Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2020Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2021Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
91713810
CY2021Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
91713810
CY2020Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
91459239
CY2020Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
91459239
CY2021Q2 us-gaap Common Stock Value
CommonStockValue
92000
CY2020Q4 us-gaap Common Stock Value
CommonStockValue
91000
CY2021Q2 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
733533000
CY2020Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
723482000
CY2021Q2 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
12000
CY2020Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-47000
CY2021Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-632571000
CY2020Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-548776000
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
101066000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
174750000
CY2021Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
269648000
CY2020Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
342940000
CY2021Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
5263000
CY2020Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
5186000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
9911000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
10648000
CY2020Q2 mcrb Revenue From Grant
RevenueFromGrant
831000
mcrb Revenue From Grant
RevenueFromGrant
1070000
CY2020Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
20099000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
65257000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-358000
CY2020Q2 mcrb Revenue From Research Agreement
RevenueFromResearchAgreement
28000
mcrb Revenue From Research Agreement
RevenueFromResearchAgreement
2016000
CY2021Q2 us-gaap Revenues
Revenues
5263000
CY2020Q2 us-gaap Revenues
Revenues
6045000
us-gaap Revenues
Revenues
10981000
us-gaap Revenues
Revenues
14234000
CY2021Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
35954000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
41842000
CY2021Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
17451000
CY2020Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
6491000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
29192000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
12629000
CY2021Q2 us-gaap Operating Expenses
OperatingExpenses
53405000
CY2020Q2 us-gaap Operating Expenses
OperatingExpenses
26590000
us-gaap Operating Expenses
OperatingExpenses
94449000
us-gaap Operating Expenses
OperatingExpenses
54471000
CY2021Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-48142000
CY2020Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-20545000
us-gaap Operating Income Loss
OperatingIncomeLoss
-83468000
us-gaap Operating Income Loss
OperatingIncomeLoss
-40237000
CY2021Q2 us-gaap Investment Income Interest
InvestmentIncomeInterest
829000
CY2020Q2 us-gaap Investment Income Interest
InvestmentIncomeInterest
74000
us-gaap Investment Income Interest
InvestmentIncomeInterest
1795000
us-gaap Investment Income Interest
InvestmentIncomeInterest
233000
CY2021Q2 us-gaap Interest Expense Debt
InterestExpenseDebt
732000
CY2020Q2 us-gaap Interest Expense Debt
InterestExpenseDebt
719000
us-gaap Interest Expense Debt
InterestExpenseDebt
1428000
us-gaap Interest Expense Debt
InterestExpenseDebt
1435000
CY2021Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-285000
CY2020Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
476000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-694000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
844000
CY2021Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-188000
CY2020Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-169000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-327000
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-48330000
CY2020Q2 us-gaap Net Income Loss
NetIncomeLoss
-20714000
us-gaap Net Income Loss
NetIncomeLoss
-83795000
us-gaap Net Income Loss
NetIncomeLoss
-40595000
CY2021Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.53
CY2020Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.28
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.91
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.56
CY2021Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
91659829
CY2020Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
73306248
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
91593845
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
72063881
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-48330000
CY2020Q2 us-gaap Net Income Loss
NetIncomeLoss
-20714000
us-gaap Net Income Loss
NetIncomeLoss
-83795000
us-gaap Net Income Loss
NetIncomeLoss
-40595000
CY2021Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax
0
CY2020Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax
0
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax
0
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax
0
CY2021Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
27000
CY2020Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
11000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
59000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
1000
CY2021Q2 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
27000
CY2020Q2 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
11000
us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
59000
us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
1000
CY2021Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-48303000
CY2020Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-20703000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-83736000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-40594000
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
-48324000
CY2020Q1 mcrb Stock Issued During Period Value At Market Equity Offerings
StockIssuedDuringPeriodValueAtMarketEquityOfferings
4178000
CY2020Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
60000
CY2020Q1 us-gaap Restricted Stock Value Shares Issued Net Of Tax Withholdings
RestrictedStockValueSharesIssuedNetOfTaxWithholdings
120000
CY2020Q1 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
249000
CY2020Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1959000
CY2020Q1 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Before Reclassification Adjustments Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax
-10000
CY2020Q1 us-gaap Net Income Loss
NetIncomeLoss
-19881000
CY2020Q1 us-gaap Stockholders Equity
StockholdersEquity
-61649000
CY2020Q2 mcrb Stock Issued During Period Value At Market Equity Offerings
StockIssuedDuringPeriodValueAtMarketEquityOfferings
14848000
CY2020Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
15000
CY2020Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1914000
CY2020Q2 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Before Reclassification Adjustments Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax
11000
CY2020Q2 us-gaap Net Income Loss
NetIncomeLoss
-20714000
CY2020Q2 us-gaap Stockholders Equity
StockholdersEquity
-65575000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
174750000
CY2021Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
372000
CY2021Q1 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
392000
CY2021Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3624000
CY2021Q1 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Before Reclassification Adjustments Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax
32000
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-35465000
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
143705000
CY2021Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
586000
CY2021Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
5078000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-8136000
CY2021Q2 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Before Reclassification Adjustments Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax
27000
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-48330000
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
101066000
us-gaap Net Income Loss
NetIncomeLoss
-83795000
us-gaap Net Income Loss
NetIncomeLoss
-40595000
us-gaap Share Based Compensation
ShareBasedCompensation
8702000
us-gaap Share Based Compensation
ShareBasedCompensation
3873000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
2902000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
3493000
mcrb Non Cash Operating Lease Cost
NonCashOperatingLeaseCost
1465000
mcrb Non Cash Operating Lease Cost
NonCashOperatingLeaseCost
1100000
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-1581000
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
102000
mcrb Noncash Interest Expense
NoncashInterestExpense
241000
mcrb Noncash Interest Expense
NoncashInterestExpense
215000
mcrb Increase Decrease In Prepaid Expenses And Other Current And Long Term Assets
IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAndLongTermAssets
-3579000
mcrb Increase Decrease In Prepaid Expenses And Other Current And Long Term Assets
IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAndLongTermAssets
-1928000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
1144000
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-9911000
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-11837000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
1684000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-700000
mcrb Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
-1012000
mcrb Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
-2163000
mcrb Increase Decrease In Accrued Expenses And Other Current And Long Term Liabilities
IncreaseDecreaseInAccruedExpensesAndOtherCurrentAndLongTermLiabilities
4395000
mcrb Increase Decrease In Accrued Expenses And Other Current And Long Term Liabilities
IncreaseDecreaseInAccruedExpensesAndOtherCurrentAndLongTermLiabilities
-29000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-69191000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-49817000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
3896000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
299000
us-gaap Payments To Acquire Investments
PaymentsToAcquireInvestments
51942000
us-gaap Payments To Acquire Investments
PaymentsToAcquireInvestments
12931000
us-gaap Proceeds From Sale Maturity And Collections Of Investments
ProceedsFromSaleMaturityAndCollectionsOfInvestments
82378000
us-gaap Proceeds From Sale Maturity And Collections Of Investments
ProceedsFromSaleMaturityAndCollectionsOfInvestments
40318000
mcrb Payments For Restricted Investments
PaymentsForRestrictedInvestments
750000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
25790000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
27088000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
957000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
75000
mcrb Proceeds From Issuance Of Common Stock And Restricted Common Stock
ProceedsFromIssuanceOfCommonStockAndRestrictedCommonStock
120000
mcrb Proceeds From At The Market Equity Offering Net Of Commissions
ProceedsFromAtTheMarketEquityOfferingNetOfCommissions
18695000
us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
392000
us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
249000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
1349000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
19139000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-42052000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-3590000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
116049000
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
65126000
CY2021Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
73997000
CY2020Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
61536000
us-gaap Interest Paid Net
InterestPaidNet
1220000
us-gaap Interest Paid Net
InterestPaidNet
1226000
mcrb Unsettled Issuance Of Common Stock From At The Market Offering
UnsettledIssuanceOfCommonStockFromAtTheMarketOffering
331000
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
4839000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
606000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
66000
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
mcrb Entity Incorporation Month And Year Of Incorporation
EntityIncorporationMonthAndYearOfIncorporation
2010-10
CY2021Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-632571000
CY2021Q2 mcrb Cash Cash Equivalents And Short And Long Term Investments
CashCashEquivalentsAndShortAndLongTermInvestments
229432000
us-gaap Net Income Loss
NetIncomeLoss
-83795000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-69191000
us-gaap Use Of Estimates
UseOfEstimates
<p style="text-indent:0.0pt;font-size:10.0pt;margin-top:6.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Use of Estimates</span></p><p style="text-indent:24.5pt;font-size:10.0pt;margin-top:6.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of revenue and expenses during the reporting periods. In the condensed consolidated financial statements, the Company uses estimates and assumptions related to revenue recognition and the accrual of research and development expenses. Estimates are periodically reviewed in light of changes in circumstances, facts and experience.</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:24.5pt;font-size:10.0pt;margin-top:6.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The full extent to which the COVID-19 pandemic will directly or indirectly impact the Company’s business, results of operations and financial condition, including revenue, operating expenses, clinical trials and employee-related amounts, will depend on future developments that are highly uncertain, including new information that may emerge concerning COVID-19 and the actions taken to contain it or treat its impact and the economic impact on local, regional, national and international markets. We have made estimates of the impact of COVID-19 within our financial statements and there may be changes to those estimates in future periods. Actual results could differ from the Company’s estimates.</span></p>
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
12177894
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
11618712
CY2021Q2 us-gaap Fair Value Assets Level1 To Level2 Transfers Amount
FairValueAssetsLevel1ToLevel2TransfersAmount
0
CY2021Q2 us-gaap Fair Value Assets Level2 To Level1 Transfers Amount
FairValueAssetsLevel2ToLevel1TransfersAmount
0
CY2020Q2 us-gaap Fair Value Assets Level1 To Level2 Transfers Amount
FairValueAssetsLevel1ToLevel2TransfersAmount
0
CY2020Q2 us-gaap Fair Value Assets Level2 To Level1 Transfers Amount
FairValueAssetsLevel2ToLevel1TransfersAmount
0
CY2021Q2 us-gaap Restricted Investments Noncurrent
RestrictedInvestmentsNoncurrent
2150000
CY2020Q4 us-gaap Restricted Investments Noncurrent
RestrictedInvestmentsNoncurrent
1400000
CY2021Q2 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
155423000
CY2021Q2 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
24000
CY2021Q2 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
12000
CY2021Q2 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
155435000
CY2020Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
187439000
CY2020Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
14000
CY2020Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
61000
CY2020Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
187392000
mcrb Cash Equivalents Original Maturity Maximum Period
CashEquivalentsOriginalMaturityMaximumPeriod
P90D
CY2021Q2 us-gaap Restricted Investments Noncurrent
RestrictedInvestmentsNoncurrent
2150000
CY2020Q4 us-gaap Restricted Investments Noncurrent
RestrictedInvestmentsNoncurrent
1400000
CY2021Q2 us-gaap Available For Sale Securities Debt Maturities Within One Year Amortized Cost
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost
140544000
CY2021Q2 us-gaap Available For Sale Securities Debt Maturities Within One Year Fair Value
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
140556000
CY2020Q4 us-gaap Available For Sale Securities Debt Maturities Within One Year Amortized Cost
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost
137588000
CY2020Q4 us-gaap Available For Sale Securities Debt Maturities Within One Year Fair Value
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
137567000
CY2021Q2 us-gaap Available For Sale Securities Debt Maturities After One Through Five Years Amortized Cost
AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost
14879000
CY2021Q2 us-gaap Available For Sale Securities Debt Maturities After One Through Five Years Fair Value
AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue
14879000
CY2020Q4 us-gaap Available For Sale Securities Debt Maturities After One Through Five Years Amortized Cost
AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost
49851000
CY2020Q4 us-gaap Available For Sale Securities Debt Maturities After One Through Five Years Fair Value
AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue
49825000
CY2021Q2 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
155423000
CY2021Q2 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
155435000
CY2020Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
187439000
CY2020Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
187392000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
3493000
CY2021Q2 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
52269000
CY2020Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
48217000
CY2021Q2 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
37222000
CY2020Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
34320000
CY2021Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
15047000
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
13897000
CY2021Q2 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
1426000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
2902000
CY2020Q2 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
1691000
CY2021Q2 mcrb Accrued Development And Clinical Manufacturing Costs Current
AccruedDevelopmentAndClinicalManufacturingCostsCurrent
12225000
CY2020Q4 mcrb Accrued Development And Clinical Manufacturing Costs Current
AccruedDevelopmentAndClinicalManufacturingCostsCurrent
6339000
CY2021Q2 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
5203000
CY2020Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
6734000
CY2021Q2 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
1485000
CY2020Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
1153000
CY2021Q2 mcrb Accrued Liabilities And Other Liabilities Current
AccruedLiabilitiesAndOtherLiabilitiesCurrent
18913000
CY2020Q4 mcrb Accrued Liabilities And Other Liabilities Current
AccruedLiabilitiesAndOtherLiabilitiesCurrent
14226000
CY2021Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
12.47
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
12.78
CY2021Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
11687959
CY2021Q2 us-gaap Long Term Debt Maturities Repayments Of Principal Remainder Of Fiscal Year
LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear
949000
CY2021Q2 us-gaap Long Term Debt Maturities Repayments Of Principal In Next Twelve Months
LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths
11970000
CY2021Q2 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Two
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo
12081000
CY2021Q2 us-gaap Long Term Debt
LongTermDebt
25000000
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
10037130
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
9.54
CY2020 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y10M13D
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
156627000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
2617056
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
23.06
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
229730
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
4.16
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
736497
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y9M25D
CY2021Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
143215000
CY2021Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
4886724
CY2021Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
11.01
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P6Y4M20D
CY2021Q2 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
66872000
CY2021Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
16.26
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
18.51
CY2020Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
2.41
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
2.17
CY2021Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
5078000
CY2020Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1914000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
8702000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3873000
mcrb Collaborative Arrangement Upfront License Fee Received
CollaborativeArrangementUpfrontLicenseFeeReceived
120000000
CY2021Q2 mcrb Contract With Customer Liability Revenue Recognized With Related Party
ContractWithCustomerLiabilityRevenueRecognizedWithRelatedParty
5263000
CY2020Q2 mcrb Contract With Customer Liability Revenue Recognized With Related Party
ContractWithCustomerLiabilityRevenueRecognizedWithRelatedParty
5203000
mcrb Contract With Customer Liability Revenue Recognized With Related Party
ContractWithCustomerLiabilityRevenueRecognizedWithRelatedParty
9911000
mcrb Contract With Customer Liability Revenue Recognized With Related Party
ContractWithCustomerLiabilityRevenueRecognizedWithRelatedParty
11837000
CY2021Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2020Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2021Q2 us-gaap Income Tax Examination Penalties And Interest Accrued
IncomeTaxExaminationPenaltiesAndInterestAccrued
0
CY2020Q4 us-gaap Income Tax Examination Penalties And Interest Accrued
IncomeTaxExaminationPenaltiesAndInterestAccrued
0

Files In Submission

Name View Source Status
0000950170-21-000674-index-headers.html Edgar Link pending
0000950170-21-000674-index.html Edgar Link pending
0000950170-21-000674.txt Edgar Link pending
0000950170-21-000674-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
mcrb-20210630.htm Edgar Link pending
mcrb-20210630.xsd Edgar Link pending
mcrb-20210630ex10_2.htm Edgar Link pending
mcrb-20210630ex10_3.htm Edgar Link pending
mcrb-20210630ex31_1.htm Edgar Link pending
mcrb-20210630ex31_2.htm Edgar Link pending
mcrb-20210630ex32_1.htm Edgar Link pending
mcrb-20210630ex32_2.htm Edgar Link pending
mcrb-20210630_cal.xml Edgar Link unprocessable
mcrb-20210630_def.xml Edgar Link unprocessable
mcrb-20210630_htm.xml Edgar Link completed
mcrb-20210630_lab.xml Edgar Link unprocessable
mcrb-20210630_pre.xml Edgar Link unprocessable
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending